Trial Profile
A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Allopurinol Compared With Allopurinol Administered Alone in Adult Subjects With Gout
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Verinurad (Primary) ; Allopurinol
- Indications Gout
- Focus Pharmacodynamics
- Sponsors Ardea Biosciences
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
- 30 Aug 2016 Status changed from active, no longer recruiting to completed.
- 12 Nov 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.